Fibroid cell growth and proliferation

Fibroid cell growth and proliferation refers to the pathological expansion of uterine leiomyoma cells, which are benign monoclonal tumors derived from the myometrium. This process is primarily driven by the ovarian steroid hormones estrogen and progesterone, which act through their respective nuclear receptors to stimulate cell division and the excessive deposition of extracellular matrix (Ciavattini et al., 2013, NIH). In uterine fibroids, the dysregulation of the cell cycle and evasion of apoptosis allow for clonal expansion, often triggered by genetic mutations such as those in the MED12 gene (Makinen et al., 2011, PubMed). Clinically, this growth leads to symptoms like heavy menstrual bleeding, pelvic pain, and infertility. Pharmacological management targets this process by inhibiting the hypothalamic-pituitary-ovarian axis using GnRH agonists (e.g., Leuprorelin) or antagonists (e.g., Elagolix) to induce a hypoestrogenic state (Stewart et al., 2017, NEJM). Additionally, selective progesterone receptor modulators (SPRMs) like Ulipristal acetate directly target the progesterone receptors within the fibroid tissue to inhibit proliferation and induce apoptosis (Donnez et al., 2012, NEJM). Other emerging therapies focus on inhibiting growth factor signaling pathways or modulating the epigenetic landscape of the fibroid cells (StatPearls, 2023).

Other names

Uterine leiomyoma proliferationMyoma growthUterine fibroid pathogenesis

Modulation of the hypothalamic-pituitary-ovarian axis to reduce systemic estrogen and progesterone levels, or direct antagonism of steroid receptors and growth factor signaling pathways to inhibit cellular division and induce apoptosis in leiomyoma cells.